Untitled

DNA Nanoswitch Calipers for Single-Molecule Proteomics
DNA nanoswitch calipers are a first-of-their-kind research tool that leverage DNA’s unique molecular qualities to study post-translational modifications on proteins to unlock a new frontier of medicine.
AminoX: Making Better Protein Drugs, Quicker and Cheaper
AminoX enables protein drugs to only become active in the tumor microenvironment and not elsewhere in the body to avoid immune-related adverse effects in the body. By designing and building non-standard amino acids into strategic positions of protein drugs, AminoX provides tumor-specific, and longer-lasting target inhibition.
Ichor: Reversing Aging
Ichor is addressing multiple age-related diseases by identifying genetic interventions that reprogram old cells to a younger state. Therapies based on these interventions could improve survival for cancer patients and long-term cardiovascular and neurological health.
Crisscross Nanoseed Detection: Nanotechnology-Powered Infectious Disease Diagnostics
This nanotech-based diagnostic platform uses a unique nucleation mechanism that assembles a DNA "nanoseed" in the presence of a pathogen-derived biomarker that then is amplified within 15 minutes to create a signal for easy detection. It is highly robust, and cost-effective, and can be adapted to detect a variety of biomarkers.
DNA Nanoswitches: “Lab-on-a-Molecule” Drug Discovery
The Lab-on-a-Molecule platform leverages the Wyss Institute’s DNA nanotechnology technology for the high-throughput, low-cost screening of a wide range of chemical and biologic compounds to enable the discovery of first-in-class therapeutics for various conditions.
Lactation Biologics: Increasing Milk Production for Healthier Babies
Lactation Biologics is developing a long-lasting, self-injectable treatment to help nursing mothers feed their babies naturally, helping them get the best nutrition possible in the face of climate disasters and supply chain disruptions.
Plastivores: Plastic-Degrading Super-Microbes and Enzymes
The Plastic Degradation project identifies microbes from natural sources that have a low-level ability to degrade multiple types of plastic. In the laboratory, with the help of synthetic biology, those microbes then are evolved into much more effective plastic-eating microbes that, in the future, could be globally deployed to decompose plastic waste.
Human Ovarian Organoids to Improve Women’s Health
Gameto is using the Wyss Institute’s fully human ovarian organoid technology to solve the global problem of rising infertility by making IVF safer, cheaper, and more accessible.
Sparkle: Instant Biosensors for Real-Time Imaging
Sparkle is revolutionizing the binder assay industry by harnessing novel chemistry to create instant fluorescent biosensors for a wide variety of uses.
Pancreatitis Tx: An Engineered Protein Treatment for Pancreatitis
First disease-modifying therapy that can be systemically applied to safely and effectively treat patients with different forms of pancreatitis.
HarborSite: Precise and Efficient Gene Editing for Next-Generation Gene Therapies
The HarborSite next-generation gene therapy platform enables integration of therapeutic genes into genomic safe harbors using highly specific and efficient recombinases to enable more predictable, safe and durable gene therapies.
Molecular Nucleic Acid Detection Technology to Empower Patients with Self-Testing Capabilities
This technology provides an innovative molecular diagnostic assay for high-speed, sensitive, and specific detection of nucleic acids from SARS-CoV-2 or other pathogens, performed in a newly devised reusable base unit with pathogen-specific, one-time-use consumables – first prototyped at the Wyss Institute, then transformed into an inexpensive, reliable and manufacturable detection system by 3EO Health.
SPEAR: Ultrasensitive Protein Detection in Small Samples
Spear Bio uses a DNA nanotechnology-driven approach developed at the Wyss Institute that allows the sensitive detection of protein biomarkers in small samples using standard instruments to create new research and diagnostic assays. An ultra-sensitive assay detecting neutralizing antibodies against SARS-CoV-2 will be the first to be commercialized.
Biotechnology for Conservation and De-Extinction
Colossal Biosciences is leveraging a suite of technologies including genome engineering to de-extinct critical species like the wooly mammoth to advance conservation to combat biodiversity loss.
Kidney Engineering Technology for New Tissue Replacement Therapies
Trestle Biotherapeutics licensed 3D bioprinting, and stem cell and kidney organoid engineering methods to help it create kidney repair and replacement therapies. These could become new standard-of-care options beyond dialysis and kidney transplants for patients with kidney failure.
SomaCode: Getting Cell Therapies Where They Need to Go
SomaCode is solving the problem of cell therapy delivery by identifying unique molecular “zip codes” for disease and engineering cells to home to those zip codes, making cell therapies safer and more effective.
Circe: Transforming greenhouse gases into valuable products with microbes
Circe Bioscience is using gas fermentation to produce valuable materials including fats, oils, and fuels from greenhouse gases using engineered microbes.
Engineered Pig Organs for Human Transplant
eGenesis is working toward ending the global transplant shortage and transforming the treatment of organ failure by using CRISPR to edit the pig genome to make their organs safe for transplant in human patients.
Targeted EPO: Safely Normalizing Oxygen Delivery in a Broad Range of Disease Conditions
General Biologics commercializes Targeted EPO as a first-in-class fusion protein therapeutic for the treatment of life-threatening and limiting hypoxia in various disease conditions, including COPD, cystic fibrosis, COVID-19, and severe anemias, such as in patients with kidney failure.

Technologies search results